Molecular cancer therapeutics: strategies for drug discovery and development
Saved in:
| Format: | Electronic eBook |
|---|---|
| Language: | English |
| Published: |
Hoboken, N.J.
Wiley-Liss
©2004
|
| Subjects: | |
| Online Access: | DE-861 DE-473 Volltext |
| Item Description: | Includes bibliographical references and index Molecular Cancer Therapeutics covers state-of-the-art strategies to identify and develop cancer drug target molecules and lead inhibitors for clinical testing. It provides a thorough treatment of drug target discovery, validation, and development. The introductory chapters provide an overview of pathways to discovery and development of molecular cancer therapeutics. Subsequent chapters progress from initial stages of drug target discovery to drug discovery, development, and testing in preclinical and clinical models. Topics include drug lead screening, drug-to-lead development, proof-of-concept studies, medicinal chemistry issues, intellectual property concerns, and clinical development. This invaluable reference promotes understanding of steps involved in developing drug leads for industrial partnering and development. It provides an overview of the strategies for discovery and validation of drug target molecules, and discusses cell- and molecule-based drug screening strategies, as well as mouse models for cancer.; Coverage also includes how to refine drug leads for suitability in clinical testing, the special issues of clinical testing of molecular-targeted drugs, and intellectual property concerns |
| Physical Description: | 1 Online-Ressource (xiv, 351 pages) |
| ISBN: | 047165616X 9780471656166 1280556730 9781280556739 |
Staff View
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043385592 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 160222s2004 xx o|||| 00||| eng d | ||
| 020 | |a 047165616X |c electronic bk. |9 0-471-65616-X | ||
| 020 | |a 9780471656166 |c electronic bk. |9 978-0-471-65616-6 | ||
| 020 | |a 1280556730 |9 1-280-55673-0 | ||
| 020 | |a 9781280556739 |9 978-1-280-55673-9 | ||
| 024 | 7 | |a 10.1002/047165616X |2 doi | |
| 035 | |a (ZDB-35-WIC)ocm85820283 | ||
| 035 | |a (OCoLC)85820283 | ||
| 035 | |a (DE-599)BVBBV043385592 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-861 | ||
| 082 | 0 | |a 616.99/4061 |2 22 | |
| 084 | |a VS 9100 |0 (DE-625)147725:253 |2 rvk | ||
| 084 | |a XH 3200 |0 (DE-625)152888:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Molecular cancer therapeutics |b strategies for drug discovery and development |c edited by George C. Prendergast |
| 264 | 1 | |a Hoboken, N.J. |b Wiley-Liss |c ©2004 | |
| 300 | |a 1 Online-Ressource (xiv, 351 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 500 | |a Molecular Cancer Therapeutics covers state-of-the-art strategies to identify and develop cancer drug target molecules and lead inhibitors for clinical testing. It provides a thorough treatment of drug target discovery, validation, and development. The introductory chapters provide an overview of pathways to discovery and development of molecular cancer therapeutics. Subsequent chapters progress from initial stages of drug target discovery to drug discovery, development, and testing in preclinical and clinical models. Topics include drug lead screening, drug-to-lead development, proof-of-concept studies, medicinal chemistry issues, intellectual property concerns, and clinical development. This invaluable reference promotes understanding of steps involved in developing drug leads for industrial partnering and development. It provides an overview of the strategies for discovery and validation of drug target molecules, and discusses cell- and molecule-based drug screening strategies, as well as mouse models for cancer.; Coverage also includes how to refine drug leads for suitability in clinical testing, the special issues of clinical testing of molecular-targeted drugs, and intellectual property concerns | ||
| 650 | 4 | |a Molecular Cell Biology | |
| 650 | 4 | |a Antineoplastic Agents / pharmacology | |
| 650 | 4 | |a Neoplasms / drug therapy | |
| 650 | 4 | |a Drug Delivery Systems | |
| 650 | 4 | |a Drug Evaluation | |
| 650 | 4 | |a Neoplasms / genetics | |
| 650 | 4 | |a Pharmacogenetics | |
| 650 | 7 | |a Antineoplastic agents / Design |2 fast | |
| 650 | 7 | |a Cancer / Chemotherapy |2 fast | |
| 650 | 7 | |a Cancer / Immunotherapy |2 fast | |
| 650 | 7 | |a Arzneimitteldesign |2 swd | |
| 650 | 7 | |a Chemotherapie |2 swd | |
| 650 | 7 | |a Cytostatikum |2 swd | |
| 650 | 7 | |a Immuntherapie |2 swd | |
| 650 | 7 | |a Krebs (Medizin) |2 swd | |
| 650 | 4 | |a Cancer / Chemotherapy | |
| 650 | 4 | |a Cancer / Immunotherapy | |
| 650 | 4 | |a Antineoplastic agents / Design | |
| 650 | 0 | 7 | |a Cytostatikum |0 (DE-588)4068347-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Immuntherapie |0 (DE-588)4026640-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Chemotherapie |0 (DE-588)4127083-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimitteldesign |0 (DE-588)4278218-1 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 0 | 1 | |a Arzneimitteldesign |0 (DE-588)4278218-1 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 689 | 1 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 1 | 1 | |a Chemotherapie |0 (DE-588)4127083-6 |D s |
| 689 | 1 | |8 2\p |5 DE-604 | |
| 689 | 2 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 2 | 1 | |a Immuntherapie |0 (DE-588)4026640-0 |D s |
| 689 | 2 | |8 3\p |5 DE-604 | |
| 700 | 1 | |a Prendergast, George C. |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 0-471-43202-4 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 978-0-471-43202-9 |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/book/10.1002/047165616X |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 3\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 912 | |a ZDB-35-WIC | ||
| 940 | 1 | |q UBG_PDA_WIC | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-028804176 | |
| 966 | e | |u https://onlinelibrary.wiley.com/doi/book/10.1002/047165616X |l DE-861 |p ZDB-35-WIC |q FRO_PDA_WIC |x Verlag |3 Volltext | |
| 966 | e | |u https://onlinelibrary.wiley.com/doi/book/10.1002/047165616X |l DE-473 |p ZDB-35-WIC |q UBG_PDA_WIC |x Verlag |3 Volltext | |
Record in the Search Index
| _version_ | 1823607507267878912 |
|---|---|
| adam_text | |
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV043385592 |
| classification_rvk | VS 9100 XH 3200 |
| collection | ZDB-35-WIC |
| ctrlnum | (ZDB-35-WIC)ocm85820283 (OCoLC)85820283 (DE-599)BVBBV043385592 |
| dewey-full | 616.99/4061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/4061 |
| dewey-search | 616.99/4061 |
| dewey-sort | 3616.99 44061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000zc 4500</leader><controlfield tag="001">BV043385592</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">160222s2004 xx o|||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">047165616X</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">0-471-65616-X</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780471656166</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-0-471-65616-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1280556730</subfield><subfield code="9">1-280-55673-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781280556739</subfield><subfield code="9">978-1-280-55673-9</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/047165616X</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-35-WIC)ocm85820283</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)85820283</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043385592</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-861</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99/4061</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 9100</subfield><subfield code="0">(DE-625)147725:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3200</subfield><subfield code="0">(DE-625)152888:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular cancer therapeutics</subfield><subfield code="b">strategies for drug discovery and development</subfield><subfield code="c">edited by George C. Prendergast</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hoboken, N.J.</subfield><subfield code="b">Wiley-Liss</subfield><subfield code="c">©2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (xiv, 351 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Molecular Cancer Therapeutics covers state-of-the-art strategies to identify and develop cancer drug target molecules and lead inhibitors for clinical testing. It provides a thorough treatment of drug target discovery, validation, and development. The introductory chapters provide an overview of pathways to discovery and development of molecular cancer therapeutics. Subsequent chapters progress from initial stages of drug target discovery to drug discovery, development, and testing in preclinical and clinical models. Topics include drug lead screening, drug-to-lead development, proof-of-concept studies, medicinal chemistry issues, intellectual property concerns, and clinical development. This invaluable reference promotes understanding of steps involved in developing drug leads for industrial partnering and development. It provides an overview of the strategies for discovery and validation of drug target molecules, and discusses cell- and molecule-based drug screening strategies, as well as mouse models for cancer.; Coverage also includes how to refine drug leads for suitability in clinical testing, the special issues of clinical testing of molecular-targeted drugs, and intellectual property concerns</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular Cell Biology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic Agents / pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms / drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Delivery Systems</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Evaluation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms / genetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacogenetics</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antineoplastic agents / Design</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer / Chemotherapy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer / Immunotherapy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Arzneimitteldesign</subfield><subfield code="2">swd</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemotherapie</subfield><subfield code="2">swd</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="2">swd</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immuntherapie</subfield><subfield code="2">swd</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Krebs (Medizin)</subfield><subfield code="2">swd</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer / Chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer / Immunotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic agents / Design</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimitteldesign</subfield><subfield code="0">(DE-588)4278218-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimitteldesign</subfield><subfield code="0">(DE-588)4278218-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Immuntherapie</subfield><subfield code="0">(DE-588)4026640-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="8">3\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Prendergast, George C.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">0-471-43202-4</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">978-0-471-43202-9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/047165616X</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-35-WIC</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">UBG_PDA_WIC</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028804176</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/047165616X</subfield><subfield code="l">DE-861</subfield><subfield code="p">ZDB-35-WIC</subfield><subfield code="q">FRO_PDA_WIC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/047165616X</subfield><subfield code="l">DE-473</subfield><subfield code="p">ZDB-35-WIC</subfield><subfield code="q">UBG_PDA_WIC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043385592 |
| illustrated | Not Illustrated |
| indexdate | 2025-02-09T19:00:42Z |
| institution | BVB |
| isbn | 047165616X 9780471656166 1280556730 9781280556739 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028804176 |
| oclc_num | 85820283 |
| open_access_boolean | |
| owner | DE-861 |
| owner_facet | DE-861 |
| physical | 1 Online-Ressource (xiv, 351 pages) |
| psigel | ZDB-35-WIC UBG_PDA_WIC ZDB-35-WIC FRO_PDA_WIC ZDB-35-WIC UBG_PDA_WIC |
| publishDate | 2004 |
| publishDateSearch | 2004 |
| publishDateSort | 2004 |
| publisher | Wiley-Liss |
| record_format | marc |
| spelling | Molecular cancer therapeutics strategies for drug discovery and development edited by George C. Prendergast Hoboken, N.J. Wiley-Liss ©2004 1 Online-Ressource (xiv, 351 pages) txt rdacontent c rdamedia cr rdacarrier Includes bibliographical references and index Molecular Cancer Therapeutics covers state-of-the-art strategies to identify and develop cancer drug target molecules and lead inhibitors for clinical testing. It provides a thorough treatment of drug target discovery, validation, and development. The introductory chapters provide an overview of pathways to discovery and development of molecular cancer therapeutics. Subsequent chapters progress from initial stages of drug target discovery to drug discovery, development, and testing in preclinical and clinical models. Topics include drug lead screening, drug-to-lead development, proof-of-concept studies, medicinal chemistry issues, intellectual property concerns, and clinical development. This invaluable reference promotes understanding of steps involved in developing drug leads for industrial partnering and development. It provides an overview of the strategies for discovery and validation of drug target molecules, and discusses cell- and molecule-based drug screening strategies, as well as mouse models for cancer.; Coverage also includes how to refine drug leads for suitability in clinical testing, the special issues of clinical testing of molecular-targeted drugs, and intellectual property concerns Molecular Cell Biology Antineoplastic Agents / pharmacology Neoplasms / drug therapy Drug Delivery Systems Drug Evaluation Neoplasms / genetics Pharmacogenetics Antineoplastic agents / Design fast Cancer / Chemotherapy fast Cancer / Immunotherapy fast Arzneimitteldesign swd Chemotherapie swd Cytostatikum swd Immuntherapie swd Krebs (Medizin) swd Cancer / Chemotherapy Cancer / Immunotherapy Antineoplastic agents / Design Cytostatikum (DE-588)4068347-3 gnd rswk-swf Immuntherapie (DE-588)4026640-0 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Chemotherapie (DE-588)4127083-6 gnd rswk-swf Arzneimitteldesign (DE-588)4278218-1 gnd rswk-swf Cytostatikum (DE-588)4068347-3 s Arzneimitteldesign (DE-588)4278218-1 s 1\p DE-604 Krebs Medizin (DE-588)4073781-0 s Chemotherapie (DE-588)4127083-6 s 2\p DE-604 Immuntherapie (DE-588)4026640-0 s 3\p DE-604 Prendergast, George C. Sonstige oth Erscheint auch als Druck-Ausgabe, Hardcover 0-471-43202-4 Erscheint auch als Druck-Ausgabe, Hardcover 978-0-471-43202-9 https://onlinelibrary.wiley.com/doi/book/10.1002/047165616X Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 3\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Molecular cancer therapeutics strategies for drug discovery and development Molecular Cell Biology Antineoplastic Agents / pharmacology Neoplasms / drug therapy Drug Delivery Systems Drug Evaluation Neoplasms / genetics Pharmacogenetics Antineoplastic agents / Design fast Cancer / Chemotherapy fast Cancer / Immunotherapy fast Arzneimitteldesign swd Chemotherapie swd Cytostatikum swd Immuntherapie swd Krebs (Medizin) swd Cancer / Chemotherapy Cancer / Immunotherapy Antineoplastic agents / Design Cytostatikum (DE-588)4068347-3 gnd Immuntherapie (DE-588)4026640-0 gnd Krebs Medizin (DE-588)4073781-0 gnd Chemotherapie (DE-588)4127083-6 gnd Arzneimitteldesign (DE-588)4278218-1 gnd |
| subject_GND | (DE-588)4068347-3 (DE-588)4026640-0 (DE-588)4073781-0 (DE-588)4127083-6 (DE-588)4278218-1 |
| title | Molecular cancer therapeutics strategies for drug discovery and development |
| title_auth | Molecular cancer therapeutics strategies for drug discovery and development |
| title_exact_search | Molecular cancer therapeutics strategies for drug discovery and development |
| title_full | Molecular cancer therapeutics strategies for drug discovery and development edited by George C. Prendergast |
| title_fullStr | Molecular cancer therapeutics strategies for drug discovery and development edited by George C. Prendergast |
| title_full_unstemmed | Molecular cancer therapeutics strategies for drug discovery and development edited by George C. Prendergast |
| title_short | Molecular cancer therapeutics |
| title_sort | molecular cancer therapeutics strategies for drug discovery and development |
| title_sub | strategies for drug discovery and development |
| topic | Molecular Cell Biology Antineoplastic Agents / pharmacology Neoplasms / drug therapy Drug Delivery Systems Drug Evaluation Neoplasms / genetics Pharmacogenetics Antineoplastic agents / Design fast Cancer / Chemotherapy fast Cancer / Immunotherapy fast Arzneimitteldesign swd Chemotherapie swd Cytostatikum swd Immuntherapie swd Krebs (Medizin) swd Cancer / Chemotherapy Cancer / Immunotherapy Antineoplastic agents / Design Cytostatikum (DE-588)4068347-3 gnd Immuntherapie (DE-588)4026640-0 gnd Krebs Medizin (DE-588)4073781-0 gnd Chemotherapie (DE-588)4127083-6 gnd Arzneimitteldesign (DE-588)4278218-1 gnd |
| topic_facet | Molecular Cell Biology Antineoplastic Agents / pharmacology Neoplasms / drug therapy Drug Delivery Systems Drug Evaluation Neoplasms / genetics Pharmacogenetics Antineoplastic agents / Design Cancer / Chemotherapy Cancer / Immunotherapy Arzneimitteldesign Chemotherapie Cytostatikum Immuntherapie Krebs (Medizin) Krebs Medizin |
| url | https://onlinelibrary.wiley.com/doi/book/10.1002/047165616X |
| work_keys_str_mv | AT prendergastgeorgec molecularcancertherapeuticsstrategiesfordrugdiscoveryanddevelopment |